|
SWISS INSTITUTE OF LONGEVITY
News
2024
The new project Sanaplas was included into the project portfolio (July 2024)
The Allogeneic Curative Serum of Sanaplas is a new therapy for moderate and severe sicca syndrome (painful eye inflammation, loss of eyesight).
More information
Tatler Asia published an interview with Gunter Festel regarding his activities in the field of longevity (April 2024)
Gunter Festel was interviewed by Tatler Asia, which is one of the premier lifestyle magazines in Asia, regarding his activities in the field of longevity in his role as founder and chairman of the Swiss Institute of Longevity.
Nanolockin has launched a sensor unit for the determination of particulate matter (April 2024)
NanoLockin has developed a sensor unit with the German company Vitrocell that can determine the interaction of particles with lung cells in real time. The new CalorQuanti can be used to optically analyse the particle dose in Vitrocell Cloud Alpha systems or as a standalone device.
Gunter Festel joined the inaugural meeting of Humansa's International Advisory Board in Hong Kong (February 2024)
In February, we had the inaugural meeting of Humansa's International Advisory Board in Hong Kong. Many interesting discussions took place in the pleasant atmosphere of the Rosewood Hotel directly on Victoria Harbour in Kawloon.
More information
2023
Gunter Festel has been appointed to the Humansa International Advisory Board (October 2023)
Gunter Festel will support Humansa in realising its strategy to establish business m0odels in the areas of longevity. Headquartered in Hong Kong, with operations across the Greater Bay Area, Humansa is the health and wellness service platform of New World Development as one of Hong Kong’s most successful companies with interests in retail, property and numerous other businesses.
More information
TriTerp has developed a patent-protected yeast technology platform to produce triterpenoids (September 2023)
TriTerp’s proprietary yeast platform opens access to chemical space of triterpenoids with estimated 20,000 molecules. With triterpenoids, many new applications are possible in the field of anti-aging and longevity. TriTerp offers various co-operation models for specific molecules ranging from out-licensing of the technology platform to joint R&D projects.
More information
Cerefort established a scientific advisory board (August 2023)
Cerefort welcomes Prof. Dr. Christine Lang, Peter Majer, Prof. Dr. Heinz Reichmann and Prof. Dr. Burkhard Schütz to its scientific advisory board. This advisory board has extensive expertise in all areas important to Cerefort, like strain development, Parkinson's prophylaxis and therapy, mitochondrial analysis and marketing/licensing know-how.
More information
Second study with Mitobene shows promising results (May 2023)
Cerefort has developed a beverage called Mitobene, which is made from grains using a patented fermentation process and has a high D-lactate content. After a first study at the beginning of 2021, another study was conducted at the end of 2022. Several persons took 100 ml of Mitobene daily over a period of 1 month. This study showed that Mitobene has a positive influence on physical performance.
More information
Aquarray's DMA technology opens the door to new paths in personalised medicine (May 2023)
Aquarray's DMA technology opens the door to new paths in personalised medicine. Due to the extreme miniaturisation of the test volumes, a few cells from biopsy material are sufficient to test the efficacy of various drugs in parallel on the patient's own cells. This makes possible a patient-specific therapy of cancer by selecting the most effective drug therapy.
More information
Nanolockin develops new air quality monitoring technology to measure ultrafine particles (April 2023)
NanoLockin has developed a new method based on lockin thermography to measure particles. This involves heating the particles with light and analyzing the heat. Compared to existing particle measuring devices, this basic physical principle of adsorption instead of light scattering can specifically detect combustion products, such as soot particles.
More information
Postitive effect on Mitochondria in the first exploratory pilot study of Cerefort (April 2023)
The participants received a defined daily doses of Mitobene with high D-lactate content. Blood was collected before and at the end of the study. Parameters of mitochondrial activity, like the Bioenergetic Health Index (BHI), were measured by the German diagnostic laboratory Biovis in Marburg. After 6 weeks of Mitobene intake, the BHI index improved and so did important parameters of mitochondrial activity, especially of the Parkinson’s patients.
More information
Aquarray launches the DMA Plate and develops the Integrated Screening System (March 2023)
Aquarray GmbH, Leopoldshafen, has been marketing the Droplet Microarray, or DMA for short, for 2 years. The DMA can be used manually as a slide, like the microtiter plate, or as a DMA plate in an automated environment. Currently, the Integrated Screening System (ISS) is being developed to illustrate the automated use of the DMA.
2022
Foundation of Triterp to commercialise a yeast technology platform for the production of Triterpenoids (October 2022)
TriTerp is a company focussed on the development of a patent-protected yeast technology platform to produce triterpenoids. The company was founded in 2022 in Switzerland to further develop and commercialise the technology.
Aquarray has first results to show within Numerous Partnerships with Equipment and Biotechnology Companies (August 2022)
Aquarray's DMA technology enables miniaturisation of screening experiments, resulting in significant material and cost savings. Recognizing the potential, numerous equipment and biotechnology companies have partnered with Aquarray to solve specific analytical problems.
More information
Aquarray further expands innovative product range and ushers in new era of screening (February 2022)
Thousand times fewer reagents and a hundred times fewer cells - this is the approach of the innovative droplet microrray technology (DMA) developed by Aquarray. The goal is to offer a fully automated screening solution for the simultaneous testing of hundreds of drugs or patient samples.
More information
2021
The development of the AirTox Monitor within NanoLockin will be funded by a Eurostars project (May 2021)
Nanolockin will develop the AirTox Monitor together with a partner in Germany. This device will be able to characterise particulate matter, which is an immense problem for public health, much better than existing devices. The development work will be funded within a Eurostars project
Foundation of the Swiss Institute of Longevity to support startup activities in this area (May 2021)
The Swiss Institute of Longevity was founded on 9th May 2021, to support early-stage start-up activities in the field of longevity. The core element is a network of scientists and experienced entrepreneurs who evaluate potential projects. After a positive evaluation, they support the start-ups, on a case-by-case basis, financially and operationally with their work and network.
.
|
